Isoliquiritigenin Suppresses Osteosarcoma U2OS Cell Proliferation and Invasion by Regulating the PI3K/Akt Signalling Pathway

Conclusion: ISL could retard proliferation and promote apoptosis of U2OS cells possibly by suppressing the PI3K/Akt signalling pathway, indicating that it might be a potential therapeutic agent for osteosarcoma treatment.Chemotherapy 2018;63:155 –161
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

Authors: Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M Abstract Introduction: Current treatment of conventional and non-conventional high-grade osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when possible, of metastases and local reccurrence, together with systemic pre- and post-operative chemotherapy with drugs that have been used since decades. Areas covered: This review is intended to summarize the new agents and therapeutic strategies that are under clinical evaluation in HGOS, with the aim to increase the cure probability of this highly malignant bone tumor, which has not...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research
ConclusionsQuantitative IVIM parameters, especially D* &f and their histogram analysis were informative and can be used as noninvasive surrogate markers for early response assessment during the course of NACT in Osteosarcoma.
Source: European Journal of Radiology - Category: Radiology Source Type: research
AZD7762 is a checkpoint kinase 1 (Chk 1) inhibitor, which has been reported to sensitize many tumor cells to DNA damage. However, whether AZD7762 could sensitize osteosarcoma cells to chemotherapy cisplatin ha...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
Conclusions: In Upper Egypt, whereas slightly less than two thirds of children with localized osteosarcoma of extremities survives their disease, metastasis at presentation remains the key predictor of dismal survival outcomes.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Original Articles Source Type: research
Publication date: August 2019Source: Journal of Bone Oncology, Volume 17Author(s): Caixia Wu, Qian Wang, Yuan LiAbstractPurposeTo investigate the feasibility of applying the dual imaging mechanisms of 99mTc-MIBI scintigraphy in predicting and evaluating the response to neoadjuvant chemotherapy in patients with osteosarcoma.Materials and methodsThirty patients with osteosarcoma who underwent both pre-and post-chemotherapy 99mTc-MIBI scintigraphy were enrolled in the study. In each patient, the tumor to background ratio (T/B), tumor washout rate (WR) of MIBI and the alteration rate (AR) of tumor uptake after chemotherapy was...
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, these investigative findings suggest that CC may play the potential anti‐invasive benefits agai nst OS through suppressing metastasis‐associated IκBα/ECT2 molecular pathway.
Source: BioFactors - Category: Biochemistry Authors: Tags: RESEARCH COMMUNICATION Source Type: research
;o Santos Birgit Geoerger Nathalie Gaspar Osteosarcoma, the most common bone malignancy with a peak incidence at adolescence, had no survival improvement since decades. Persistent problems are chemo-resistance and metastatic spread. We developed in-vitro osteosarcoma models resistant to chemotherapy and in-vivo bioluminescent orthotopic cell-derived-xenografts (CDX). Continuous increasing drug concentration cultures in-vitro resulted in five methotrexate (MTX)-resistant and one doxorubicin (DOXO)-resistant cell lines. Resistance persisted after drug removal except for MG-63. Different resistance mechanisms were ide...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusion.Apatinib is a sensitive drug for advanced osteosarcoma with a high response rate after failure of chemotherapy, with similar duration of response compared to other TKIs.Implications for Practice.For advanced osteosarcoma progressing upon chemotherapy, antiangiogenesis tyrosine kinase inhibitors (TKIs) have been proved to be effective in prolonging the progression‐free survival in previous multicenter trials and have been included into new National Comprehensive Cancer Network guidelines as second‐line therapy. Apatinib is a TKI that specifically inhibits vascular endothelial growth factor receptor‐2, which...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: New Drug Development and Clinical Pharmacology, Sarcomas Source Type: research
Authors: Mian A, Singal AK, Bakhshi S, Sood R, Vikram NK, Ray A Abstract A 21-year old female, recently diagnosed with osteosarcoma of right humerus, presented to the emergency with history of fever, productive cough, chest pain and progressive respiratory distress for six days. Initial investigations suggested pneumonia but she did not respond to parenteral antibiotics. CT pulmonary angiogram revealed bilateral pulmonary artery embolism. Thrombolysis was performed using alteplase, which failed to improve the clinical condition. In view of underlying malignancy, a possibility of tumour-embolism was considered and s...
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
Publication date: Available online 9 July 2019Source: Journal of Bone OncologyAuthor(s): Caixia Wu, Qian Wang, Yuan LiAbstractPurposeTo investigate the feasibility of applying the dual imaging mechanisms of 99mTc-MIBI scintigraphy in predicting and evaluating the response to neoadjuvant chemotherapy in patients with osteosarcoma.Materials and methodThirty patients with osteosarcoma who underwent both pre-and post-chemotherapy 99mTc-MIBI scintigraphy were enrolled in the study. T/B value, tumor washout rate (WR) before chemotherapy and alteration rate (AR) of tumor uptake after chemotherapy was evaluated respectively. Based...
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
More News: Antidoxidants | Bone Cancers | Cancer & Oncology | Chemotherapy | Flavonoids | Osteosarcoma | Study